Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.61 |
| ▸ | RAF1 | P04049 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.61 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 4/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3737793 | 0.99 | KDR (0.60) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL4276210 | 0.89 | KDR (0.60) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL3733006 | 0.87 | MAPK10 (0.65) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL5797537 | 0.85 | KDR (0.55) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL4848887 | 0.85 | KDR (0.62) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL4844219 | 0.84 | KDR (0.64) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL4848688 | 0.84 | KDR (0.58) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL5796912 | 0.84 | KDR (0.53) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL4851040 | 0.82 | KDR (0.61) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL4847094 | 0.81 | KDR (0.65) | KDRRAF1LCKRETCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150290235-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB SCIENCE (FR) | 2015-10-15 | — | — | US | disclosed |
| EP-2922572-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB Science (FR) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079709-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB SCIENCE (FR) | 2014-05-30 | — | — | WO | disclosed |
| US-7829717-B2 | (Arylamidoaryl)squaramide compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829717-B2 | (Arylamidoaryl)squaramide compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829717-B2 | (Arylamidoaryl)squaramide compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7388012-B2 | (Hydrazido)(amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-7388012-B2 | (Hydrazido)(amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060111349-A1 | (Arylamidoaryl)squaramide compounds | OSI PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2006034111-A1 | (ARYLAMIDOARYL)SQUARAMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111349-A1 | (Arylamidoaryl)squaramide compounds | KIT, TSSK6, MCTS1 | KDR 1120/4885RAF1 833/4885LCK 549/4885 |
| US-20150290235-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | DCK, ADK, DTYMK | KDR 802/4885RAF1 573/4885LCK 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.